Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The…
Oslo, Norway, 20 May 2026 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the…
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian…
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 28 April 2026 – 6 PM CET Disclosure of transparency notification from BlackRock, Inc.…
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study…
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in…
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen…
Männedorf, Switzerland, March 17, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a strategic collaboration with NVIDIA…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global…
Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5, 2026. The Board of Directors of Sanofi has…